Научные статьи \ Прикладные науки. Медицина. Технология \ Mедицинские науки \ Патология. Клиническая медицина \ Заболевания опорно-двигательной системы. Скелет и мышечная система

Эффективность и безопасность применения ритуксимаба при ревматоидном артрите (новые данные)

Эффективность и безопасность применения ритуксимаба при ревматоидном артрите (новые данные)

Автор: Кусевич Д.А., Авдеева А.С.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Форум молодых ученых

Статья в выпуске: 4 т.55, 2017 года.

Бесплатный доступ

Ревматоидный артрит (РА) - аутоиммунное ревматическое заболевание, характеризующееся хроническим эрозивным артритом (синовитом) и системным воспалительным поражением внутренних органов, приводящим к ранней инвалидизации и ухудшению качества жизни пациентов. Накопленные данные об эффективности, безопасности и экономической эффективности применения анти-В-клеточной терапии позволяют выделить ритуксимаб (РТМ) как чрезвычайно важный препарат первой или второй линии терапии генноинженерными биологическими препаратами, после неэффективного лечения ингибиторами фактора некроза опухоли а (ФНОа). В связи с этим по-прежнему актуальной остается проблема персонифицированного выбора схемы лечения в каждом конкретном случае. Опыт применения РТМ в клинической практике свидетельствует о его высокой эффективности в отношении как клинических проявлений, так и влияния на качество жизни пациентов при развернутом РА, характеризующемся лекарственной резистентностью к базисным противовоспалительным препаратам и ингибиторам ФНОа, а также при раннем РА. В настоящее время в литературе представлено большое количество данных, посвященных роли предшествующей терапии, влиянию стадии РА при назначении и различных курсовых доз РТМ в эффективности терапии РА, часть из которых будет обсуждена в данном обзоре.

Еще

Ревматоидный артрит, активность заболевания, ритуксимаб, эффективность терапии, безопасность терапии

Короткий адрес: https://sciup.org/14945842

IDR: 14945842   |   DOI: 10.14412/1995-4484-2017-420-428

The efficacy and safety of rituximab in rheumatoid arthritis: new evidence

Rheumatoid arthritis (RA) is an autoimmune rheumatic disease characterized by chronic erosive arthritis (synovitis) and a systemic inflammatory lesion of the internal organs, which results in early disability and worse quality of life in patients. The accumulated data on the efficacy, safety, and cost-effectiveness of anti-B cell therapy allow identification of rituximab (RTM) as an extremely important drug of first- or second-line therapy with biological agents after ineffective treatment with tumor necrosis factor-а (TNF-а) inhibitors. In this connection, the choice of a personalized treatment regimen remains relevant in each specific case as before. Clinical experience with RTM suggests that the drug is highly effective in improving both clinical manifestations and quality of life in patients with active RA that is characterized by resistance to disease-modifying antirheumatic drugs and TNF-а inhibitors, as well as in those with early RA. The current literature presents a large amount of data on the role of prior therapy and the impact of the stage of RA when using different RTM doses on its efficiency, some of which will be discussed in this review.

Еще

Список литературы Эффективность и безопасность применения ритуксимаба при ревматоидном артрите (новые данные)

  • Насонов ЕЛ, Каратеев ДЕ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008
  • Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013
  • Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861-71 DOI: 10.1016/S0140-6736(07)60784-3
  • Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012
  • Насонов ЕЛ. Фармакотерапия ревматоидного артрита -взгляд в 21 век. Клиническая медицина. 2005;(6):8-12
  • Leandro MJ, Cooper N, Cambridge G, et al. Bone-marrow В-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford). 2007;46(1):29-36 DOI: 10.1093/rheumatology/kel148
  • Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5 Pt 1):859-66 DOI: 10.1111/j.1600-6143.2006.01288.x
  • Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated В cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory В cells correlates with clinical response. Arthritis Res Ther. 2009;11:R131 DOI: 10.1186/ar2798
  • Roll P, Palanichamy A, Kneitz C, et al. Regeneration of В cell subsets after transient depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377-86 DOI: 10.1002/art.22019
  • Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of В cell depletion. Arthritis Rheum. 2011;63(3):603-8 DOI: 10.1002/art.30152
  • Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab; mechanisms of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917-25 DOI: 10.1136/ard.2007.080960
  • Edwards JC, Szcezepanski L, Szechinski J, et al. Efficacy of В-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-81 DOI: 10.1056/NEJMoa032534
  • Насонов ЕЛ. Фармакотерапия ревматоидного артрита в XXI веке: фокус на ритуксимаб. Современная ревматология. 2009;3(4):67-75
  • Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther. 2015;2:99-111 DOI: 10.1007/s40744-015-0016-9
  • Porter D, Melckebeke J, Dale J, et al. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016;388:239- DOI: 10.1016/S0140-6736(16)00380-9
  • Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2015;74:979-84 DOI: 10.1136/annrheumdis-2013-203993
  • Torrente-Segarra V, Acosta Pereira A, Morla R, et al. VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist. Reumatol Clin. 2016;12(6):319-22 DOI: 10.1016/j.reuma.2015.11.019
  • Keyser FD, Hoffman I, Durez P, et al. Longterm followup of rit-uximab therapy in patients with rheumatoid arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis Registry. J Rheumatol. 2014;41;1761-5 DOI: 10.3899/jrheum.131279
  • Harrold LR, Reed GW, Shewade A, et al. Effectiveness of rituximab for the treatment of rheumatoid arthritis in patients with prior exposure to anti-TNF: results from the CORRONA registry. J Rheumatol. 2015;42:1090-8 DOI: 10.3899/jrheum.141043
  • Wendler J, Burmester G R, Sörensen H, et al. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients Arthritis Res Ther. 2014,16:R80 DOI: 10.1186/ar4521
  • Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50 DOI: 10.1186/s13075-016-0951-z
  • Ferraccioli G, Tolusso В, Gremese E. Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons? Arthritis Res Ther. 2016;18:126 DOI: 10.1186/s13075-016-1022-1
  • Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomized controlled trial. Ann Rheum Dis. 2014;73(8):1508-14 DOI: 10.1136/annrheumdis-2013-203480
  • Tvete IF, Natvig B, Gasemyr J, et al. Comparing effects of biologic agents in treating patients with rheumatoid arthritis: A multiple treatment comparison regression analysis. PLoS ONE. 2015;10(9):e0137258 DOI: 10.1371/journal.pone.0137258
  • Bredemeier M, Campos GG, de Oliveira FK. Updated systematic review and meta-analysis of randomized controlled trials comparing low-versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol. 2015;34(10);1801-5 DOI: 10.1007/s10067-015-2977-z
  • Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502 DOI: 10.1136/annrheumdis-2012-201956
  • Van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm safety of Rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial program over 11 years. J Rheumatol. 2015;42:1761-6 DOI: 10.3899/jrheum.150051
  • Vassilopoulos D, Delicha EM, Settas L, et al. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study Clin Exper Rheumatol. 2016;34:893-900.
  • Aaltonen KJ, Joensuu JT, Virkki L, et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol. 2015;42;372-8 DOI: 10.3899/jrheum.140853
  • Harrold LR, Reed GW, Karki C, et al. Risk of infection associated with subsequent biologic agent use after rituximab: Results from a National Rheumatoid Arthritis Patient Registry. Arthritis Care Res. 2016;68(12):1888-93 DOI: 10.1002/acr.22912
  • Tsai-Ling Liao, Ching-Heng Lin, Yi-Ming Chen, et al. Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: A nationwide retrospective cohort study in Taiwan PLOS ONE. April 11, 2016 DOI: 10.1371/journal.pone.0153217
  • Silva-Fernandez L, Lunt M, Kearsley-Fleet L, et al, on behalf of the British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid. Arthritis Rheum. 2016;55:20332039 DOI: 10.1093/rheumatology/kew314
  • Solomon DH, Kremer JM, Fisher M, et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic dugs. Semin Arthritis Rheum. 2014;43(4):489-97 DOI: 10.1016/j.semarthrit.2013.08.003
  • Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692-701 DOI: 10.1002/art.21675
  • Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev. 2006;15:2069-77 DOI: 10.1158/1055-9965.EPI-06-0300
  • Salmon JH, Cacoub P, Combe B, et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1:e000034 DOI: 10.1136/rmdopen-2014-000034
  • Stamatopoulos K, Papadaki T, Pontikoglou C, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with lateonset neutropenia. Leukemia. 2008;22:1446-9 DOI: 10.1038/sj.leu.2405077
  • Dunleavy K, Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005;106:795-802 DOI: 10.1182/blood-2004-08-3198
  • Marotte H, Paintaud G, Watier H, Miossec P. Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann Rheum Dis. 2008;67:893-4 DOI: 10.1136/ard.2007.081166
  • Giraud C, Tatar Z, Soubrier M. Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis Clin Rheumatol. 2016;35:2615-8 DOI: 10.1007/s10067-016-3379-6
  • Herzog-Tzarfati K, Shiloah E, Koren-Michowitz M, et al. Successful treatment of prolonged agranulocytosis caused by acute parvovirus B19 infection with intravenous immunoglobulins. Eur J Intern Med. 2006;17:439-40 DOI: 10.1016/j.ejim.2006.02.014
  • Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586-97 DOI: 10.1056/NEJMra030840
  • Brown KE, Young NS. Parvoviruses and bone marrow failure. Stem Cells Dayt Ohio. 1996;14:151-63 DOI: 10.1002/stem.140151
  • Pham T, Fautrel B, Gottenberg JE, et al. Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine. 2008;75 Suppl 1:S1-99.
  • Pritchard CH, Greenwald M, Kremer JM, et al. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. BMC Musculoskelat Disord. 2014;15:177-81 DOI: 10.1186/1471-2474-15-177
  • Can M, Alibaz-Oner F, Yimaz-Oner S, et al. Accelerated infusion rates of rituximab are well-tolerated and safe in rheumatology practice: a single-center experience. Clin Rheumatol. 2013;32(1):87-90 DOI: 10.1007/s10067-012-2094-1
  • Larsen JL, Jacobsen S. Rapid infusion with rituximab: short term safety in systemic autoimmune diseases. Rheumatol Int. 2013;33(2):529-33 DOI: 10.1007/s00296-011-2208-0
  • Manders SHM, Kievit W, Adang E, et al. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multicentre randomised trial. Arthritis Res Ther. 2015;17:134 DOI: 10.1186/s13075-015-0630-5
  • Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1-278 DOI: 10.3310/hta15140
  • Hallinen TA, Soini EJ, Eklund K, Puolakka K. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology. 2010;49:767-77 DOI: 10.1093/rheumatology/kep425
  • Quartuccio L, Di Bidino R, Ruggeri M, et al. Cost-effectiveness analysis of two rituximab retreatment regimens for longstanding rheumatoid arthritis Arthritis Care Res. 2015;67(7):947-55 DOI: 10.1002/acr.22534
  • Cohen S, Emery P, Greenwald M, et al. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Br J Clin Pharmacol. 2016;82:129-38 DOI: 10.1111/bcp.12916
  • Насонов ЕЛ, Зонова ЕВ, Иванова ОН и др. Результаты сравнительного клинического исследования III фазы препаратов ритуксимаба (Ацеллбия® и Мабтера®) при ревматоидном артрите (исследование BIORA). Научно-практическая ревматология. 2016;54(5):510-9
  • Gerlag DM, Safy M, Maijer KI, et al. A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA . Arthritis Rheum. 2016;68 Suppl 10. Available from: http://acrabstracts.org/abstract/a-single-infusion-of-rituximab-delays-the-onset-of-arthritis-in-subjects-at-high-risk-of-developing-ra/. Accessed May 20, 2017.
  • Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015 Jan 20;1:CD007356 DOI: 10.1002/14651858
Еще
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp